Japan
# |
Name |
Net Cash Used For Investing Activities |
Reported Date | Stock Price |
Change |
Price (30 days) | Country |
---|---|---|---|---|---|---|---|
1 |
USD 57.41 M
|
March 31, 2024 | USD 24.50 | -0.22% |
|
Japan |
|
2 |
USD 39.13 M
|
March 31, 2024 | USD 14.33 | -1.63% |
|
Japan |
|
3 |
USD 9.23 M
|
Dec. 31, 2023 | USD 12.89 | -3.06% |
|
Japan |
|
4 |
USD 5.24 M
|
March 31, 2024 | USD 0.92 | -1.38% |
|
Japan |
|
5 |
USD -38.21 K
|
Dec. 31, 2023 | USD 3.76 | 2.75% |
|
Japan |
|
6 |
USD -50.53 K
|
March 31, 2024 | USD 0.28 | 0.04% |
|
Japan |
|
7 |
USD -88.98 K
|
June 30, 2024 | USD 1.01 | 1.37% |
|
Japan |
|
8 |
USD -220.37 K
|
March 31, 2024 | USD 0.17 | 0.04% |
|
Japan |
|
9 |
USD -959.39 K
|
Dec. 31, 2023 | USD 2.63 | -0.70% |
|
Japan |
|
10 |
USD -1.92 M
|
Dec. 31, 2023 | USD 9.57 | -3.49% |
|
Japan |
|
11 |
USD -2.67 M
|
Dec. 31, 2023 | USD 1.21 | -0.50% |
|
Japan |
|
12 |
USD -4.70 M
|
March 31, 2024 | USD 11.63 | 0.67% |
|
Japan |
|
13 |
USD -17.77 M
|
March 31, 2024 | USD 3.51 | 6.45% |
|
Japan |
|
14 |
USD -40.60 M
|
March 31, 2024 | USD 9.54 | -0.95% |
|
Japan |
|
15 |
USD -5.59 B
|
March 31, 2024 | USD 9.47 | 0.08% |
|
Japan |
The Vaccines company in Japan with the highest Net Cash Used For Investing Activities is Kissei Pharmaceutical Co., Ltd. (Tokyo Stock Exchange: 4547.T) at USD 57.41 M.
The Vaccines company in Japan with the lowest Net Cash Used For Investing Activities is Astellas Pharma Inc. (Tokyo Stock Exchange: 4503.T) at USD -5.59 B.
The top 10 Vaccines companies in Japan by Net Cash Used For Investing Activities are Kissei Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., PeptiDream Inc., NanoCarrier Co., Ltd., Oncolys BioPharma Inc., BrightPath Biotherapeutics Co., Ltd., Soiken Holdings Inc., OncoTherapy Science, Inc., RaQualia Pharma Inc. and Mizuho Medy Co.,Ltd..
The bottom 10 Vaccines companies in Japan by Net Cash Used For Investing Activities are Astellas Pharma Inc., Santen Pharmaceutical Co., Ltd., JCR Pharmaceuticals Co., Ltd., WDB Holdings Co., Ltd., SymBio Pharmaceuticals Limited, Mizuho Medy Co.,Ltd., RaQualia Pharma Inc., OncoTherapy Science, Inc., Soiken Holdings Inc. and BrightPath Biotherapeutics Co., Ltd..